Discussion
Efgartigimod, a treatment approved for certain autoimmune diseases, was linked to maintained clinical responses and low disease activity scores for up to 72 weeks in people with Sjögren’s disease, according to data from a small Phase 2 clinical trial and its open-label extension study. Participants who showed a clinical…